Graham Capital Management’s Xeris Biopharma Holdings XERS Stock Holding History

Graham Capital Management’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$158K	Buy	+27,162	New	+$180K	0.01%	991
2025 Q3	–	Sell	-125,417	Closed	-$586K	–	1720
2025 Q2	$586K	Sell	125,417 -8,251	-6%	-$37.8K	0.02%	757
2025 Q1	$734K	Buy	133,668 +63,006	+89%	+$254K	0.02%	652
2024 Q4	$240K	Buy	70,662 +17,209	+32%	+$55.4K	0.01%	1019
2024 Q3	$152K	Sell	53,453 -1,688	-3%	-$4.33K	0.01%	968
2024 Q2	$124K	Sell	55,141 -31,478	-36%	-$63.4K	﹤0.01%	918
2024 Q1	$191K	Buy	86,619 +49,835	+135%	+$129K	0.01%	906
2023 Q4	$86.4K	Sell	36,784 -20,625	-36%	-$38.1K	﹤0.01%	916
2023 Q3	$107K	Buy	+57,409	New	+$132K	﹤0.01%	933

Other funds holding XERS

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Qube Research & Technologies (QRT)

Qube Research & Technologies (QRT) London, United Kingdom $70.4B AUM 20.22% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $244M AUM 80.12% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return